Valuation: H&R GmbH & Co KgaA

Market Cap 203M 232M 187M 174M 330M 22.13B 334M 2.24B 872M 10.87B 871M 852M 37.67B P/E 2026 *
34.7x
P/E 2027 * 25.6x
Enterprise Value 359M 410M 331M 307M 583M 39.14B 591M 3.96B 1.54B 19.21B 1.54B 1.51B 66.61B EV / Sales 2026 *
0.28x
EV / Sales 2027 * 0.27x
Free-Float
21.97%
Yield 2026 *
0.92%
Yield 2027 * 0.92%
05-15 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-31 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-28 Kepler Cheuvreux Favors BASF and Bayer, Avoids H&R and Evonik DP
11-14 H&R GmbH & Co. KGaA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
11-14 H&R GmbH & Co. KGaA Revises Earnings Guidance for the Full Year 2025 CI
25-08-24 Nils Hansen acquired additional 7.78% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?15 million. CI
25-08-15 H&R GmbH & Co. KGaA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Nils Hansen proposed to acquire remaining 38.55% stake in H&R GmbH & Co. KGaA from Srs Schmierstoff Vertrieb GmbH, ÖLfabrik Wilhelm Scholten GmbH, Wilhelm Scholten Beteiligungen GmbH and others for ?73 million. CI
25-05-13 H&R GmbH & Co. KGaA Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-04-16 H&R GmbH & Co. KGaA announces Annual dividend, payable on May 30, 2025 CI
25-04-08 H&R GmbH & Co. KGaA Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-03-26 H&R GmbH & Co. KGaA Says Postponement Of The Publication Of The Consolidated Financial Statements And The Annual Report 2024 RE
25-03-26 H&R GmbH & Co. KGaA Announces Postponement of the Publication of the Consolidated Financial Statements and the Annual Report 2024 CI
Manager TitleAgeSince
Chief Executive Officer 61 2015-12-31
Investor Relations Contact - 2005-12-31
Director TitleAgeSince
Chairman 62 2012-04-16
Director/Board Member 71 2011-04-30
Director/Board Member 69 2011-04-30
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 232M
-1.50%+2.83%+11.38%+38.61% 131B
-6.09%+25.00%+537.93%+161.30% 48.89B
-0.38%-2.54%-8.72%-41.60% 41.56B
+2.66%-1.07%+31.30%-17.73% 31.91B
+2.87%+1.88%+31.98%+61.54% 22.01B
-4.29%-3.35%+383.41%+602.60% 19.68B
-0.61%-3.73%+73.26%+272.15% 19.63B
+5.28%+1.63%+31.79%+28.01% 18.46B
-0.22%-0.87%+83.02%+1.36% 17.91B
Average -0.23%+1.79%+130.59%+122.91% 39B
Weighted average by Cap. -1.04%+3.20%+114.50%+84.75%

Financials

2026 *2027 *
Net sales 1.29B 1.48B 1.19B 1.11B 2.1B 141B 2.13B 14.26B 5.55B 69.15B 5.55B 5.42B 240B 1.33B 1.52B 1.23B 1.14B 2.16B 145B 2.19B 14.67B 5.71B 71.12B 5.7B 5.58B 247B
Net income 5.85M 6.68M 5.39M 5M 9.5M 637M 9.62M 64.48M 25.1M 313M 25.08M 24.53M 1.08B 8M 9.13M 7.36M 6.84M 12.98M 871M 13.16M 88.15M 34.31M 427M 34.28M 33.53M 1.48B
Net Debt 156M 178M 144M 133M 253M 17B 257M 1.72B 670M 8.35B 669M 655M 28.94B 158M 180M 145M 135M 256M 17.19B 260M 1.74B 677M 8.44B 677M 662M 29.26B
Logo H&R GmbH & Co KgaA
H&R GmbH & Co KGaA is a Germany-based manufacturing of chemical and pharmaceutical speciality products. The Company’s two business activities are chemicals and pharmaceutical raw materials and precision plastic parts. It operates through three segments: ChemPharm Refining, ChemPharm Sales and Plastics. The ChemPharm Refining segment, which produces oils, technical and medical white oils as well as paraffins and wax products; the ChemPharm Sales segment, which produces plasticizers and wax emulsions and the Plastics segment manufacturing precision plastic parts as well as assemblies and medical consumables.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-